BIVI BIOVIE INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1580149 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-22.3%
TTM EPS YoY54.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-143.7%
ROA-119.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets40.9%
Debt / equity0.00x
Current ratio2.40x
Interest coverage-1,363.57x
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-19.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $13.96M | $9.27M | $23.10M | $33.30M | $17.26M |
| SG&A expense | $8.51M | $8.57M | $8.85M | $11.55M | $9.77M |
| Operating income | -$22.65M | -$18.07M | -$32.18M | -$45.08M | -$27.25M |
| Interest expense | $17,901 | $332,720 | $2.89M | $4.30M | $2.16M |
| Net income | -$22.07M | -$17.54M | -$32.12M | -$50.26M | -$26.08M |
| EPS (basic) | -3.05 | -12.12 | -73.05 | -15.47 | -1.06 |
| EPS (diluted) | -3.05 | -12.12 | -73.05 | -15.47 | -1.06 |
| Weighted avg. shares (diluted) | 7.25M | 1.48M | 451,853 | 3.25M | 24.66M |
| Balance sheet | |||||
| Cash & equivalents | $8.98M | $17.54M | $23.84M | $19.46M | $18.64M |
| Current assets | $13.64M | $20.70M | $24.05M | $34.04M | $18.78M |
| Goodwill | $345,711 | $345,711 | $345,711 | $345,711 | $345,711 |
| Intangibles | — | $178,341 | $407,718 | $637,095 | $866,472 |
| Total assets | $14.25M | $21.56M | $25.21M | $35.10M | $20.11M |
| Current liabilities | $3.80M | $2.27M | $9.35M | $14.49M | $4.17M |
| Total liabilities | $3.98M | $2.55M | $9.70M | $19.76M | $16.44M |
| Shareholders' equity | $10.27M | $19.01M | $15.51M | $15.34M | $3.67M |
| Shares outstanding | 7.54M | 1.91M | 619,008 | 3.64M | 24.98M |
| Cash flow statement | |||||
| Operating cash flow | -$19.02M | -$19.03M | -$27.95M | -$40.25M | -$18.99M |
| Investing cash flow | — | — | $14.53M | -$14.30M | — |
| Financing cash flow | $10.46M | $12.73M | $17.80M | $55.37M | $33.12M |
| Stock-based compensation | $2.28M | $1.20M | $2.82M | $4.22M | $5.81M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.